Novo Nordisk Oral Semaglutide Yields 3.2% More Weight Loss, Faces Duopoly Pressure
Novo Nordisk’s 25 mg oral semaglutide delivered 3.2% greater weight loss than Lilly’s 36 mg orforglipron in a simulated ORION study treatment comparison involving overweight or obese adults. A November patient survey found 84% of respondents preferred characteristics matching oral semaglutide, underscoring strong early demand ahead of patent expirations on injectables.
1. Efficacy Data from ORION Study
A simulated treatment comparison from the ORION study showed Novo Nordisk’s 25 mg oral semaglutide achieved an average 3.2% greater weight loss versus Lilly’s 36 mg orforglipron in overweight or obese adults without diabetes, highlighting a measurable efficacy advantage.
2. Patient Preference Signals
In a November survey of overweight or obese adults with weight-related conditions, 84% of respondents favored treatment attributes aligned with oral semaglutide, suggesting strong early demand that could steer prescribing decisions as oral therapies gain traction.
3. Competitive Outlook and Patent Risks
With FDA approvals now secured for both companies’ oral obesity treatments, Novo Nordisk and Eli Lilly are poised in a direct duopoly, while upcoming patent expirations on key injectable GLP-1 therapies introduce long-term risks to market dominance.